ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) 29.3% HIGHER; announced pivotal Phase III -020 Study with pimavanserin in patients with Parkinson’s disease ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE